Hormone Research in Paediatrics

Original Paper

Adult Height in Patients Treated for Isolated Growth Hormone Deficiency: Role of Birth Weight

Di Cesare Merlone A.a · Bozzola E.a · Castelnovi C.a · Chiabotto P.b · Costante L.b · De Sanctis L.b · Tinelli C.c · Bozzola M.a

Author affiliations

aDepartment of Pediatrics, University of Pavia, Pavia; bPediatric Endocrinology, Regina Margherita Hospital, Torino and cBiometrics Unit, IRCCS San Matteo, Pavia, Italy

Related Articles for ""

Horm Res 2005;63:102–106

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 08, 2004
Accepted: January 24, 2005
Published online: April 06, 2005
Issue release date: April 2005

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP

Abstract

To evaluate the effect of growth hormone (GH) administration on adult height (AH) in two groups of isolated GH-deficient (IGHD) children born either small (birth weight below –2 SD) or appropriate (birth weight above –2 SD) for gestational age (GA). Out of 35 prepubertal IGHD children, 14 small for GA (SGA, group A) and 21 appropriate for GA (AGA, group B) were examined. All patients received continuous GH treatment at a median dose of 0.028 mg/kg/day (range 0.023–0.032) in group A and 0.024 (range 0.023–0.028) in group B. GH treatment was administered for a period of 67.0 months (range 42.37–96.05) in group A and 54.31 months (range 47.14–69.31) in group B. All children were measured using a Harpenden stadiometer every 6 months until they reached AH (growth velocity <1 cm/year). The patients underwent a retesting a few months after stopping GH therapy. A significant difference was found between group A and B as expected for birth weight SD, –2.70 (range –2.87 to –2.29) and –0.73 (range –1.30 to 0.14) respectively (p < 0.000001) and interestingly also for body mass index SDS (BMI SDS) at retesting, 0.08 (range 0.30 to –1.51) and 0.61 (range 0.73 to –1.10) respectively (p < 0.04). We observed no significant differences between groups A and B in height (expressed as the SDS for chronological age, height SDS) at diagnosis (p = 0.75), height SDS at start of puberty (p = 0.51), height SDS at retesting (p = 0.50), target height SDS (TH SDS) (p = 0.47), AH SDS (p = 0.92), corrected height SDS (height SDS – TH SDS) (p = 0.60), BMI SDS at diagnosis (p = 0.25), GH dosage (p = 0.34) and therapy duration (p = 0.52). GH treatment with a standard dose in short IGHD children leads to a normalization of AH without any significant difference between SGA and AGA patients.

© 2005 S. Karger AG, Basel




Related Articles:


References

  1. Albanese A, Stanhope R: Growth and metabolic data following growth hormone treatment of children with intrauterine growth retardation. Horm Res 1993;39:8–12.
  2. Chatelain P: Children born with intrauterine growth retardation or small for gestational age: Long-term growth and metabolic consequences. Endocr Regul 2000;34:33–36.
  3. Hokken-Koelega ACS, De Ridder MAJ, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: Do they catch-up? Pediatr Res 1995;38:267–271.
  4. Albertsson-Wikland K, Karlberg J: Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr Suppl 1994;399:64–70.
  5. Karlberg J, Albertsson-Wikland K: Growth in full-term small-for-gestational-age infants: From birth to final height. Pediatr Res 1995;38:733–739.
  6. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega ACS: Growth hormone treatment in children with short stature born small for gestational age: Five-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999;84:3064–3070.
  7. De Zegher F, Albertsson-Wikland K, Wollmann HA, Chatelain P, Chaussain JL, Lofstrom A, et al: Growth hormone treatment of short children born small for gestational age: Growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 2000;85:2816–2821.
  8. Balsamo A, Tassoni P, Cassio A, et al: Response to growth hormone therapy in patients with growth hormone deficiency who at birth were small or appropriate in size for gestational age. J Pediatr 1995;126:474–477.
  9. Chatelain PG, Cauderay MC, De Zegher F, et al: Growth hormone secretion and sensitivity in children born small for gestational age. Acta Pediatr Suppl 1996;417:15–16.
  10. De Zegher F, Maes M, Gargosky SE, Heinrichs C, Du Caju MVL, Thiry G, De Schepper J, Craen M, Breysem L, Löfström A, Jönsson P, Bourguignon JP, Malvaux P, Rosenfeld RG: High-dose growth hormone treatment of short children born small for gestational age. J Clin Endocrinol Metab 1996;81:1887–1892.
  11. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: Result of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88:3584–3590.
  12. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976;51:170–179.
  13. Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA, et al: Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 1997;82:402–406.
  14. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM: Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth. Diabetologia 1993;36:62–67.
  15. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS: Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;341:938–941.
  16. Phillips DI, Barker DJ, Hales CN, Hirst S, Osmond C: Thinness at birth and insulin resistance in adult life. Diabetologia 1994;37:150–154.
  17. De Zegher F, Ong K, Van Helvoirt M, Mohn A, Wodds K, Dunger D: High-dose growth hormone (GH) treatment in non GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab 2002;87:148–151.
  18. Boguszewski M, Albertsson-Wikland K, Aronsson S, Gustafsson J, Hagenas L, Westgren U, et al: Growth hormone treatment of short children born small-for-gestational-age: The Nordic Multicentre Trial. Acta Paediatr 1998;87:257–263.
  19. Sas T, Mulder P, Hokken-Koelega ACS: Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 2000;85:3786–3792.
  20. De Zegher F, Albertsson-Wikland K, Wilton P, Chatelain P, Jonsson B, Lofstrom A, et al: Growth hormone treatment of short children born small for gestational age: A metanalysis of four independent, randomized, controlled, multicentre studies. Acta Paediatr Suppl 1996;417:27–31.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 08, 2004
Accepted: January 24, 2005
Published online: April 06, 2005
Issue release date: April 2005

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP